MetaStat, Inc. to Present at the 26th Annual ROTH Conference
26 Février 2014 - 1:15PM
Marketwired
MetaStat, Inc. to Present at the 26th Annual ROTH Conference
MONTCLAIR, NJ--(Marketwired - Feb 26, 2014) - MetaStat, Inc.
(OTCQB: MTST), a life science company focused on understanding and
treating systemic metastasis, announced today that it has been
invited to present at the upcoming 26th Annual ROTH Conference. The
conference will be held on March 9-12, 2014 at The Ritz-Carlton
Laguna Niguel in Dana Point, California. MetaStat will be
presenting on Wednesday, March 12, 2014 at 12:30 pm (PT).
MetaStat's Chief Executive Officer, Oscar Bronsther, M.D., will
present an overview of the company and provide an update on
MetaStat's novel diagnostic and therapeutic approaches to systemic
metastasis, the process by which cancer spreads from a primary
tumor through the bloodstream to other areas of the body.
Dr. Bronsther stated, "With our recently completed MetaSite
Breast™ trial and the opening of our drug discovery
laboratory, we believe we are well positioned to deliver our breast
cancer diagnostics to the market in 2015 and validate our novel
drug targets." Dr. Bronsther continued, "We believe this is a great
opportunity to create visibility and investor awareness for our
company and we are excited to have the opportunity to present at
the ROTH Conference."
To arrange a one-on-one meeting with management, please contact
Robert Haag at mtst@irthcommunications.com or 1-866-976-4784.
About the 26th Annual
ROTH Conference The annual ROTH Conference is one of the
largest of its kind in the U.S., bringing together executives from
hundreds of growth companies. This event is designed to provide
investors with a unique opportunity to gain insight into emerging
growth companies across a variety of sectors, including Cleantech,
Consumer & Retail, Energy & Industrial, Enterprise
Software, Healthcare, Resources, Semiconductors & Electronics,
Services and Technology & Media. The conference will feature
company presentations, Q&A sessions, expert panels and
thousands of management one-on-one and small group meetings.
About MetaStat,
Inc.
MetaStat is a life sciences company that develops and
commercializes diagnostic products and novel therapeutics for the
early and reliable prediction and treatment of systemic metastasis,
the process by which cancer spreads from a primary tumor through
the bloodstream to other areas of the body. MetaStat is focused on
breast, prostate, lung and colorectal cancers, where systemic
metastasis is responsible for approximately 90% of all deaths. The
Company's function-based diagnostic platform technology is based on
the identification and understanding of the pivotal role of the
mena protein and its isoforms, a common pathway for the development
of systemic metastatic disease in all epithelial-based solid
tumors. Both the MetaSite Breast™ and MenaCalc™ product
lines are designed to accurately stratify patients based on their
individual risk of metastasis and to allow clinicians to better
"customize" cancer treatment decisions by positively identifying
patients with a high-risk of metastasis who need aggressive therapy
and by sparing patients with a low-risk of metastasis from the
harmful side effects and expense of chemotherapy. Additionally, the
MenaBloc™ therapeutic program aims to build upon mena biology and
alternative splicing events as a driver of disease progression to
exploit novel targets that provide precision medicines in
oncology.
Forward-Looking
Statements
This press release contains "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, and such forward-looking statements are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause
future circumstances, events or results to differ materially from
those projected in the forward-looking statements as a result of
various factors and other risks, including those set forth in the
Company's Form 10-K filed with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and the company undertakes
no obligation to update such statements.
Contact IRTH
Communications Robert Haag 1-866-976-4784
mtst@irthcommunications.com MetaStat, Inc. Daniel Schneiderman Vice
President (973) 744-7618 dan@metastat.com
MetaStat (CE) (USOTC:MTST)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
MetaStat (CE) (USOTC:MTST)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024